title: Placenta-derived gp96 as a multivalent prophylactic cancer vaccine.
abstract: A major challenge for designing prophylactic cancer vaccines is to define immunogenic and safe cancer antigens. Given the striking similarity of antigen expression patterns between cancer and embryonic tissues, we defined a prototype strategy of using placenta-derived heat shock protein gp96, which induces prophylactic anti-tumor T cell responses. Immunization with placental gp96 provided partial protection and long-term (at least 3 months) anti-tumor immunity against growth of transplantable melanoma or breast tumors in mice, elicited total protection against 7, 12-dimethylbenz(a)-anthracene (DMBA)-induced mammary tumors in rats, and significantly reduced the occurrence and growth of autochthonous breast tumors in HER2 transgenic mice. Placental gp96 activated HER2- and MUC1-specific T cell responses through binding to tumor-associated antigens. Our results reveal the novel immunogenicity of placental gp96 and its potential use as a multivalent cancer vaccine.
authors.affiliation: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
authors.forename: Bao
authors.initials: B
authors.lastname: Zhao
authors.forename: Yanzhong
authors.initials: Y
authors.lastname: Wang
authors.forename: Bo
authors.initials: B
authors.lastname: Wu
authors.forename: Shan
authors.initials: S
authors.lastname: Liu
authors.forename: Erjie
authors.initials: E
authors.lastname: Wu
authors.forename: HongXia
authors.initials: H
authors.lastname: Fan
authors.forename: MingMing
authors.initials: M
authors.lastname: Gui
authors.forename: Lizhao
authors.initials: L
authors.lastname: Chen
authors.forename: Changfei
authors.initials: C
authors.lastname: Li
authors.forename: Ying
authors.initials: Y
authors.lastname: Ju
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Songdong
authors.initials: S
authors.lastname: Meng
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D010920:Placenta / Q000276:immunology*; D011247:Pregnancy; D011485:Protein Binding; D051381:Rats; D016176:T-Lymphocyte Subsets / Q000276:immunology; D047368:Tumor Burden
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C052646:sarcoma glycoprotein gp96 rejection antigens